Applied Spectral Imaging

Applied Spectral Imaging

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $19.5M

Overview

Applied Spectral Imaging is a long-established, revenue-generating private company specializing in digital diagnostic solutions for cytogenetics and pathology. Its core technology encompasses automated slide scanning, image analysis, and workflow software for fluorescence and brightfield imaging, serving clinical and research laboratories. As a subsidiary of ZYTOMICS, ASI leverages combined expertise in imaging and reagents to offer integrated end-to-end laboratory solutions. The company holds FDA clearances and IVDR compliance, with a strong international distribution network supporting its commercial operations.

OncologyGenetics

Technology Platform

Scanner-agnostic and probe-agnostic software and hardware platforms for digital cytogenetics (karyotyping, FISH) and digital pathology (H&E, IHC). Supports brightfield, fluorescence, and spectral imaging with automated analysis, workflow management, and LIS integration.

Funding History

4
Total raised:$19.5M
Series A$8M
Grant$1.5M
Series A$8M
Seed$2M

Opportunities

The global shift to digital pathology and automated cytogenetics creates a large, growing market.
ASI's agnostic platform strategy appeals to labs seeking to avoid vendor lock-in.
The integration with ZYTOMICS enables offering end-to-end laboratory solutions, expanding its addressable market beyond imaging software.

Risk Factors

Faces intense competition from large medtech firms and agile software startups.
Successful integration with parent company ZYTOMICS is critical but carries execution risk.
Slow adoption rates for digital workflows in clinical labs and the need for continuous regulatory compliance are additional challenges.

Competitive Landscape

ASI competes in the digital pathology and cytogenetics software market against major players like Roche (Ventana), Philips, Leica Biosystems, and Akoya Biosciences, as well as specialized software companies. Its key differentiator is a scanner-agnostic and probe-agnostic open platform, providing labs with flexibility compared to closed, proprietary ecosystems.